Linezolid is a synthetic antibacterial of the oxazolidinone class that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit, preventing the formation of a functional 70S initiation complex.

Indicated for nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections (including diabetic foot infections), and infections due to vancomycin-resistant Enterococcus faecium.

For adults and adolescents, the typical dose is 600 mg IV every 12 hours, with duration depending on the infection (10–28 days); pediatric patients receive 10 mg/kg IV every 8 hours.

Most common adverse reactions (>5% of adult and/or pediatric patients treated with Linezolid Injection) include: diarrhea, vomiting, headache, nausea, and anemia.

Hypersensitivity to linezolid or its components, and concurrent use with monoamine oxidase inhibitors (MAOIs) or use within two weeks of taking an MAOI.

Includes risks of myelosuppression (especially with prolonged use), peripheral and optic neuropathy, serotonin syndrome, Clostridioides difficile-associated diarrhea, lactic acidosis, and potential for drug interactions with serotonergic and adrenergic agents.